SEARCH

SEARCH BY CITATION

References

  • 1
    Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23:170.
  • 2
    Wolf P, Hofer A, Legat FJ et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160:1869.
  • 3
    Gambichler T, Tigges C, Scola N et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol 2011; 164:13836.
  • 4
    Lynde CW, Gupta AK, Guenther L et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat 2012; 23:2617.
  • 5
    De Simone C, D'Agostino M, Capizzi R. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol 2011; 21:56872.
  • 6
    Wolf P, Hofer A, Weger W et al. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed 2011; 27:1869.
  • 7
    Wolf P, Weger W, Legat FJ et al. Treatment of 311-nm ultraviolet B-enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol 2012; 166:14753.
  • 8
    Legat FJ, Hofer A, Wackernagel A et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007; 143:101622.
  • 9
    Zane C, Capezzera R, Venturini M et al. A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study. Dermatology 2009; 218:3216.
  • 10
    Calzavara-Pinton P. Narrowband ultraviolet B and biologics in psoriasis. Br J Dermatol 2012; 166:5.
  • 11
    Wainwright NJ, Dawe RS, Ferguson J. Narrowband ultraviolet B (TL-01) phototherapy for psoriasis: which incremental regimen? Br J Dermatol 1998; 139:41014.
  • 12
    Park KK, Wu JJ, Koo J. A randomized, ‘head-to-head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol 2012 Jun 15 [Epub ahead of print].
  • 13
    Bashir MM, Sharma MR, Werth VP. TNF-α production in the skin. Arch Dermatol Res 2009; 301:8791.
  • 14
    Boonstra A, Savelkoul HF. The role of cytokines in ultraviolet-B induced immunosuppression. Eur Cytokine Netw 1997; 8:11723.
  • 15
    Faurschou A, Gniadecki R, Wulf HC. Infliximab inhibits DNA repair in ultraviolet B-irradiated premalignant keratinocytes. Exp Dermatol 2008; 17:9338.
  • 16
    Tsuru K, Horikawa T, Budiyanto A et al. Low-dose ultraviolet B radiation synergizes with TNF-α to induce apoptosis of keratinocytes. J Dermatol Sci 2001; 26:20916.
  • 17
    Gambichler T, Tigges C, Dith A et al. Impact of etanercept treatment on ultraviolet B-induced inflammation, cell cycle regulation and DNA damage. Br J Dermatol 2011; 164:11015.
  • 18
    Sheikh MS, Antinore MJ, Huang Y, Fornace AJ Jr. Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor 1. Oncogene 1998; 17:255563.
  • 19
    Aragane Y, Kulms D, Metze D et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 1998; 140:17182.
  • 20
    Muthusamy V, Piva TJ. The UV response of the skin: a review of the MAPK, NFκB and TNFα signal transduction pathways. Arch Dermatol Res 2010; 302:517.
  • 21
    Tjioe M, Gerritsen MJ, Den Broeder AA et al. Adalimumab, a fully human anti-TNF-α monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patients. Exp Dermatol 2003; 12:4605.
  • 22
    Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143:71926.
  • 23
    Margolis D, Bilker W, Hennessy S et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137:77883.
  • 24
    Lebwohl M, Blum R, Berkowitz E et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005; 141:8614.
  • 25
    Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895904.
  • 26
    Greenberg J, Strand V, Keystone E et al. TNF inhibitors (TNF-I) and risk of malignancy in 8,072 RA patients followed over 15,495 patient years. Abstract 282, American College of Rheumatology 71st Annual Meeting, Boston, MA, 6–11 November 2007.
  • 27
    Askling J. Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998–2006. Ann Rheum Dis 2009; 68:423.
  • 28
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large U.S. observational study. Arthritis Rheum 2007; 56:288695.
  • 29
    Mercer LK, Galloway JB, Lunt M et al. The influence of anti-TNF therapy upon incidence of non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR). Abstract presented at the ACR/ARPH Scientific Meeting, Philadelphia, PA, 17–21 October 2009.
  • 30
    National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance TA103. Etanercept and Efalizumab for the Treatment of Adults with Psoriasis. London: National Institute for Health and Clinical Excellence, 2006.